Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 68Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Recurrence 23Lymphoma, B-Cell 22Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

Carboplatin 786Pemetrexed 609Cisplatin 547Paclitaxel 491pembrolizumab 465Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61tislelizumab 60Cyclophosphamide 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × ibrutinib × Clear all
NCT02321540 2023-10-25

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
13 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

NCT02950038 2017-02-13

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡